Skip to Content
COVID-19 Resources
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 01/25/17

Information below provided by the Pharmaceutical Company.

Ipilimumab (YERVOY®)

Agent Description

Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa.

Mechanism of Action

CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T cell responsiveness, including the anti-tumor immune response.

Classification

Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86.

Molecular Targets

N/A

Monograph

See package insert: http://packageinserts.bms.com/pi/pi_yervoy.pdf External Link

Studies of Interest

Areas of interest:

  • Bladder: studies in various lines of therapy with nivolumab/ipilimumab plus standard of care (BCG, chemo)

Areas NOT of interest:

  • Ipilimumab monotherapy in metastatic melanoma patients (exception is ipilimumab in patients that progress on anti-PD1)
  • Ipilimumab monotherapy in adjuvant stage 3 melanoma patients (exception is special populations like mucosal and uveal)
  • Ipilimumab combinations with standard of care in metastatic melanoma
  • Ipilimumab combinations with radiation in melanoma
  • Nivolumab/ipilimumab/cabozantinib combination in renal cell carcinoma

Information collaborator would like included in investigator proposals

N/A